What is FidoCure?
FidoCure is at the forefront of veterinary personalized medicine, specializing in canine cancer treatment. By leveraging genomic testing, the company develops tailored therapeutic strategies for dogs, aiming to improve treatment efficacy and patient outcomes. FidoCure's innovative approach focuses on the unique genetic makeup of each canine patient, offering advanced options to veterinarians and pet owners. The company is building the world's largest proprietary cancer data set for dogs, which is crucial for enhancing the understanding and development of new cancer treatments in veterinary medicine. This focus on data-driven innovation positions FidoCure as a leader in the rapidly evolving field of pet healthcare.
How much funding has FidoCure raised?
FidoCure has raised a total of $10M across 1 funding round:
Other Financing Round
$10M
Other Financing Round (2020): $10M with participation from Borealis Ventures, Lerer Hippeau, Tau Ventures, Polaris Partners, Andreessen Horowitz, and Y-Combinator
Key Investors in FidoCure
Borealis Ventures
Borealis Ventures is a venture capital firm dedicated to building visionary healthcare companies, focusing on essential elements for success and supporting innovative solutions within the healthcare sector.
Lerer Hippeau
Lerer Hippeau is a venture capital firm that invests in early-stage startups, particularly those with innovative ideas and the potential to tackle challenging problems, across both enterprise and consumer landscapes.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, partnering with entrepreneurs to create successful business solutions and foster innovation.
What's next for FidoCure?
With the recent major strategic investment, FidoCure is poised for significant expansion and further development of its personalized canine cancer treatment platform. The company's focus on building a comprehensive genomic data set for canine cancers suggests a strategic direction towards enhancing diagnostic capabilities and refining treatment protocols. Future initiatives will likely involve scaling its services to reach a broader veterinary network, deepening research into novel therapeutic targets, and potentially exploring strategic partnerships within the broader animal health and biotechnology sectors. This sustained capital and strategic backing indicate a strong market validation and a clear path toward establishing FidoCure as a dominant force in veterinary oncology.
See full FidoCure company page
